NEW YORK (GenomeWeb News) – Rules-Based Medicine said today it will work with start-up drug firm Psynova Neurotech to develop and sell a biomarker-based blood test that could be used to help diagnose schizophrenia.
The companies will work together to validate, seek regulatory approval for, and manufacture the schizophrenia test, which RBM will sell exclusively worldwide.
Psynova discovered the biomarkers the companies will test through a collaboration with the Cambridge Centre for Neuropsychiatric Research at the Institute of Biotechnology, Cambridge University. Those collaborators processed samples using RBM’s HumanMAP multiplex platform.
Current diagnosis of schizophrenia is highly subjective and time consuming, the company said, and the biomarker-based tests will help general practitioners and psychiatrists diagnose and treat patients early on, while their symptoms are mild.
Psynova Neurotech was founded by University of Cambridge researchers Sabine Bahn and Chris Lowe, and was funded by Porton Capital.
Financial terms of the agreement were not released.